Letter to the editorSuccessful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation
References (6)
- et al.
Complement in human diseases: lessons from complement deficiencies
Mol Immunol
(2009) - et al.
Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency
Rheumatology
(2007) - et al.
The role of complement in the early immune response to transplantation
Nat Rev Immunol
(2012)
There are more references available in the full text version of this article.
Cited by (57)
The autoimmune rheumatological presentation of Common Variable Immunodeficiency Disorders with an overview of genetic testing
2024, Seminars in Arthritis and RheumatismMonogenic lupus: Tracing the therapeutic implications from single gene mutations
2023, Clinical ImmunologyInborn Errors of Immunity and Autoimmune Disease
2023, Journal of Allergy and Clinical Immunology: In PracticeThe complement system and human autoimmune diseases
2023, Journal of AutoimmunityMacrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue
2022, Autoimmunity ReviewsIntertwined pathways of complement activation command the pathogenesis of lupus nephritis
2022, Translational ResearchCitation Excerpt :C1q antibodies in SLE patients are associated with proliferative LN, and may specify the activity of renal disease.70 Therapeutic success was achieved using fresh frozen plasma or hematopoietic stem cell transplantation to treat C1q-deficient SLE patients.71,72 Taken together, the human and mouse data advise that specific modulation of the classical pathway using inhibitors or activators of complement may reduce the kidney damage associated with LN.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.